Paradigm Biopharmaceuticals . Share Price and Company Fundamentals
Last traded: Today at 3:44 AM
Paradigm Biopharmaceuticals Limited, a biopharmaceutical company, engages in the research and development of therapeutic products for human use in Australia. It offers pentosan polysulphate sodium drugs in the injectable form for the treatment of bone marrow edema, respiratory, and alphaviral arthritis diseases. The company was incorporated in 2014 and is based in Melbourne, Australia.
|Primary activities||Biopharmaceutical company focused on repurposing the drug, pentosan polysulphate sodium, for the lead clinical indication of bone marrow edema|
|Industry / Sector||Biotechnology / Healthcare|
|Mailing address||500 Collins Street Level 15 Melbourne VIC 3000 Australia|
|Phone / Fax||/|
|Share registry||COMPUTERSHARE INVESTOR SERVICES PTY LIMITED|
Paradigm Biopharmaceuticals . does not pay dividends.
As of May 2021, following are the company executives and directors listed on Paradigm Biopharmaceuticals ..
|Mr. Paul John Rennie BSc, Grad Dip, MBM, MSTC||CEO, MD & Exec. Chairman||61||632.36k|
|Mr. Justin Cahill||Chief Financial Officer|
|Dr. Jeannette Joughin||Chief Operating Officer|
|Dr. Ravi Krishnan||Chief Scientific Officer|
|Ms. Simon White||Director of Investor Relations|
|Dr. Michael Imperiale||Global Head of Safety|
|Dr. Donna L. Skerrett||Chief Medical Officer & Exec. Director||63|
|Ms. Beverley Huttmann||Commercial Head|
|Ms. Michelle Coffey||Global Head of Regulatory Affairs|
|Mr. Kevin G. Hollingsworth||Company Sec.||67|
Profitability and management effectiveness
Return on assets
Return on equity
Profitability ratios are a class of financial metrics that are used to assess a business's ability to generate earnings relative to its revenue, operating costs, balance sheet assets, and shareholders' equity over time, using data from a specific point in time.
The return on equity signifies how well the management is running the company in terms of capital management. The ideal return on equity is greater than 10%. The return on equity is calculated as net income divided by total share holders equity.
Valuation and Trading Info
The market capitalization of Paradigm Biopharmaceuticals . is 485.84M and its enterprise value is 444.28M. The enterprise value to revenue ratio of PAR is 144.42.
The PAR's stocks Beta value is 1.61 making it 61% more volatile compared to ASX market index. Technology stocks and small caps tend to have higher betas than the market benchmark. This indicates that adding the stock to a portfolio will increase the portfolio’s risk, but also increase its expected return. On the other hand utility stocks often have low betas because they tend to move more slowly than market averages.
Companies similar to Paradigm Biopharmaceuticals . (PAR)
Paradigm Biopharmaceuticals . (ASX:PAR) Frequently Asked Questions
1. What is Paradigm Biopharmaceuticals .'s Stock Symbol?
Paradigm Biopharmaceuticals . trades on ASX under the ticker symbol "PAR".
2. What is Paradigm Biopharmaceuticals .'s stock price today?
One share of PAR stock can currently be purchased for approximately $2.12.
3. How can I contact Paradigm Biopharmaceuticals .?
Paradigm Biopharmaceuticals .'s mailing address is 500 Collins Street Level 15 Melbourne VIC 3000 Australia. The company can be reached via phone at .
4. What is Paradigm Biopharmaceuticals .'s official website?
The official website of Paradigm Biopharmaceuticals . is http://www.paradigmbiopharma.com.
5. Which share registry manages Paradigm Biopharmaceuticals .'s stock?
Paradigm Biopharmaceuticals .'s stock is managed by COMPUTERSHARE INVESTOR SERVICES PTY LIMITED.